Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
76 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amino Acid Loss During Continuous Renal Replacement Therapy
NCT06659835
Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease
NCT01423045
Incidence of Acute Kidney Injury and Mortality in Critically Ill Patients: Urinary Chloride as a Prognostic Marker
NCT05542927
Ultrasound Assessment of Volume in Patients on Continuous Dialysis
NCT03194750
Renal Physiology During Continuous Renal Replacement Therapy
NCT04114747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High fluid intake
fluid intake of 4 litres per day
high fluid intake
fluid intake of 4 litres per day
normal fluid intake
Fluid intake of 2 litres per day
normal fluid intake
Fluid intake of 2 litres per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
high fluid intake
fluid intake of 4 litres per day
normal fluid intake
Fluid intake of 2 litres per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An effective glomerular filtration rate (eGFR) according the MDRD formula between 20 and 75ml/min/1.73m2
* Ejection fraction \>20%
* Absence of liver cirrhosis or ascites
* No evidence of active glomerulonephritis or immunosuppressive therapy if native kidney disease
* Acute transplant rejection
* Urinary protein excretion below 3g/d
* Age between 18 and 70 years.
Exclusion Criteria
* Severe pulmonary disease
* Mean arterial pressure (MAP) \> 120 mm Hg
* Pregnancy
* Kidney transplantation within three months prior to randomization
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical University Vienna
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Haas, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OFS1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.